Katie M. Phillips
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katie M. Phillips has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad R. Sedaghat
Department of Otolaryngology–Head and Neck Surgery University of Cincinnati College of Medicine Cincinnati Ohio USA
22 shared publications Firas A. Houssein
Department of Otolaryngology—Head and Neck Surgery University of Cincinnati College of Medicine Cincinnati Ohio USA
7 shared publicationsStacey T. Gray
Department of Otolaryngology—Head and Neck Surgery Massachusetts Eye and Ear Infirmary Harvard Medical School Boston Massachusetts USA
6 shared publicationsDavid S. Caradonna
Department of Otolaryngology, Harvard Medical School, Boston, MA, USA
5 shared publicationsMarlene M. Speth
Department of Otorhinolaryngology Kantonsspital Aarau Aarau Switzerland
5 shared publicationsAhmad R. Sedaghat
Department of Otolaryngology—Head and Neck Surgery University of Cincinnati College of Medicine Cincinnati Ohio USA
4 shared publications
Latest Publications
- 23 October 2026
- Published by Wiley in International Forum of Allergy & Rhinology
Comparison of Chronic Rhinosinusitis Disease Control Classification Using the Chronic Rhinosinusitis Control Test Versus EPOS Criteria
Introduction: The objective of this study was to compare classification of CRS control using EPOS criteria and the Chronic Rhinosinusitis Control Test (CRCT) in a real‐world cohort of chronic rhinosinusitis (CRS) patients. Methods: CRS control was classified as controlled, partly controlled, or uncontrolled in 305 participants using EPOS and CRCT‐based classifications. Metrics of CRS disease burden included Overall Symptom Severity (OSS), disease‐specific (SNOT‐22) and general health‐related (EQ‐5D VAS) quality of life, and endoscopic disease burden (modified Lund–Kennedy [MLK] score). Convergent and divergent validity were determined by comparing CRS disease burden across different levels of CRS control for each classification scheme. Results: There was 35.7% agreement ( κ = 0.366, p < 0.001) between CRS control classification using the CRCT compared to the EPOS criteria. Consistent with how patients and providers have been previously shown to classify CRS control, the CRCT classified more participants as having controlled and partly controlled CRS compared to the EPOS criteria, which heavily skewed toward classifying participants as having uncontrolled CRS. The CRCT control classifications demonstrated convergent and divergent validity by reflecting appropriate levels of disease burden with significant differences between control classes. The EPOS classifications of controlled and partly controlled CRS lacked divergent validity, and the EPOS classification of uncontrolled CRS lacked convergent validity by including patients with very mild CRS disease burden. Conclusion: Compared to the classification scheme proposed by the EPOS guidelines, the classification of CRS control by the CRCT more closely aligns with patients’ and providers’ assessments of CRS control and has greater convergent and divergent validity.
- 23 October 2026
- Published by Wiley in International Forum of Allergy & Rhinology
Comparison of Chronic Rhinosinusitis Disease Control Classification Using the Chronic Rhinosinusitis Control Test Versus EPOS Criteria
Introduction: The objective of this study was to compare classification of CRS control using EPOS criteria and the Chronic Rhinosinusitis Control Test (CRCT) in a real‐world cohort of chronic rhinosinusitis (CRS) patients. Methods: CRS control was classified as controlled, partly controlled, or uncontrolled in 305 participants using EPOS and CRCT‐based classifications. Metrics of CRS disease burden included Overall Symptom Severity (OSS), disease‐specific (SNOT‐22) and general health‐related (EQ‐5D VAS) quality of life, and endoscopic disease burden (modified Lund–Kennedy [MLK] score). Convergent and divergent validity were determined by comparing CRS disease burden across different levels of CRS control for each classification scheme. Results: There was 35.7% agreement ( κ = 0.366, p < 0.001) between CRS control classification using the CRCT compared to the EPOS criteria. Consistent with how patients and providers have been previously shown to classify CRS control, the CRCT classified more participants as having controlled and partly controlled CRS compared to the EPOS criteria, which heavily skewed toward classifying participants as having uncontrolled CRS. The CRCT control classifications demonstrated convergent and divergent validity by reflecting appropriate levels of disease burden with significant differences between control classes. The EPOS classifications of controlled and partly controlled CRS lacked divergent validity, and the EPOS classification of uncontrolled CRS lacked convergent validity by including patients with very mild CRS disease burden. Conclusion: Compared to the classification scheme proposed by the EPOS guidelines, the classification of CRS control by the CRCT more closely aligns with patients’ and providers’ assessments of CRS control and has greater convergent and divergent validity.
- Open Access
- 9 June 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (11) , 1249-1259
Translation and Cross‐Cultural Adaptation of the Chronic Rhinosinusitis Control Test for Global Use
Introduction: The Chronic Rhinosinusitis Control Test (CRCT) is a patient‐reported outcome measure (PROM) written in English that is psychometrically validated to measure chronic rhinosinusitis control. Because the availability of translated PROMs is a driver of data equity—collection of data that is fair and generally representative—our objective was to create a library of translated, cross‐culturally adapted versions of the CRCT that could ultimately be used for patients worldwide. Methods: A hybrid approach leveraging generative artificial intelligence (genAI) in collaboration with expert human linguists was employed for translation and cross‐cultural adaptation of the CRCT. For each target language, forward translations were performed with three large language models (LLMs) (ChatGPT, Copilot, and Perplexity) after which an expert human linguist provided additional revisions that were used to create a consensus final translation. Backward translations were performed using LLMs (Claude, Copilot, and Perplexity). The accuracy and validity of translations at each step were assessed qualitatively and quantitatively. Results: The translation and cross‐cultural adaptation of the CRCT was achieved into 37 languages: Arabic, Bengali, Brazilian Portuguese, Bulgarian, Cantonese Chinese, Czech, Danish, Dutch, European Portuguese, Filipino, Finnish, French, German, Greek, Hebrew, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Mandarin Chinese, Norwegian, Persian, Polish, Punjabi, Romanian, Russian, Serbo‐Croatian, Spanish, Swahili, Swedish, Thai, Turkish, Ukrainian, Urdu, and Vietnamese. These translated, cross‐culturally adapted versions of the CRCT are made available in this article. Conclusion: Translated, cross‐culturally adapted versions of the CRCT developed in this study promote data equity by serving as a basis for psychometric validation of the CRCT for worldwide use.
- 9 June 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (11) , 1249-1259
Open AccessTranslation and Cross‐Cultural Adaptation of the Chronic Rhinosinusitis Control Test for Global Use
Introduction: The Chronic Rhinosinusitis Control Test (CRCT) is a patient‐reported outcome measure (PROM) written in English that is psychometrically validated to measure chronic rhinosinusitis control. Because the availability of translated PROMs is a driver of data equity—collection of data that is fair and generally representative—our objective was to create a library of translated, cross‐culturally adapted versions of the CRCT that could ultimately be used for patients worldwide. Methods: A hybrid approach leveraging generative artificial intelligence (genAI) in collaboration with expert human linguists was employed for translation and cross‐cultural adaptation of the CRCT. For each target language, forward translations were performed with three large language models (LLMs) (ChatGPT, Copilot, and Perplexity) after which an expert human linguist provided additional revisions that were used to create a consensus final translation. Backward translations were performed using LLMs (Claude, Copilot, and Perplexity). The accuracy and validity of translations at each step were assessed qualitatively and quantitatively. Results: The translation and cross‐cultural adaptation of the CRCT was achieved into 37 languages: Arabic, Bengali, Brazilian Portuguese, Bulgarian, Cantonese Chinese, Czech, Danish, Dutch, European Portuguese, Filipino, Finnish, French, German, Greek, Hebrew, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Mandarin Chinese, Norwegian, Persian, Polish, Punjabi, Romanian, Russian, Serbo‐Croatian, Spanish, Swahili, Swedish, Thai, Turkish, Ukrainian, Urdu, and Vietnamese. These translated, cross‐culturally adapted versions of the CRCT are made available in this article. Conclusion: Translated, cross‐culturally adapted versions of the CRCT developed in this study promote data equity by serving as a basis for psychometric validation of the CRCT for worldwide use.
- Open Access
- 8 June 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (12) , 5262-5270
Validity and Responsiveness of Chronic Rhinosinusitis Control Test Subdomains
Objective: The chronic rhinosinusitis control test (CRCT) is a patient‐reported outcome measure that measures, quantifies, and classifies CRS control. The CRCT has a sinonasal subdomain and an impairment subdomain. The objective of this study is to psychometrically validate the CRCT subdomains. Methods: A cohort of 701 adult CRS patients was recruited and completed a CRCT, as well as overall symptom severity (OSS), SNOT‐22, and EQ‐5D quality of life (QOL) questionnaires. A subset of participants completed these questionnaires at a second time point to establish responsiveness to change ( N = 283). Psychometric validation was performed by establishing criterion validity and responsiveness for the CRCT subdomain scores in these CRS patients. Minimal clinically important difference (MCID) values for improvement/worsening were determined for the CRCT subdomain scores using distribution‐based and anchor‐based methods. Results: The CRCT sinonasal and impairment subdomain scores significantly correlate with and are responsive to measures of CRS symptom severity (OSS), CRS‐specific QOL (SNOT‐22), and general QOL (EQ‐5D). The CRCT sinonasal subdomain is more reflective of sinonasal symptom burden and has an MCID for improvement/worsening of ≥ 3 points, while the impairment subdomain is more reflective of general QOL and has an MCID for improvement/worsening of ≥ 1 point. Conclusions: The CRCT sinonasal and impairment subdomain scores may serve as psychometrically validated outcome measures that provide additional insights into a patient's CRS disease state and overall CRS control in addition to the CRCT score. MCID values for the CRCT subdomain scores may serve as benchmarks for judging change in the subdomain scores. Level of Evidence: N/A
- 8 June 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (12) , 5262-5270
Open AccessValidity and Responsiveness of Chronic Rhinosinusitis Control Test Subdomains
Objective: The chronic rhinosinusitis control test (CRCT) is a patient‐reported outcome measure that measures, quantifies, and classifies CRS control. The CRCT has a sinonasal subdomain and an impairment subdomain. The objective of this study is to psychometrically validate the CRCT subdomains. Methods: A cohort of 701 adult CRS patients was recruited and completed a CRCT, as well as overall symptom severity (OSS), SNOT‐22, and EQ‐5D quality of life (QOL) questionnaires. A subset of participants completed these questionnaires at a second time point to establish responsiveness to change ( N = 283). Psychometric validation was performed by establishing criterion validity and responsiveness for the CRCT subdomain scores in these CRS patients. Minimal clinically important difference (MCID) values for improvement/worsening were determined for the CRCT subdomain scores using distribution‐based and anchor‐based methods. Results: The CRCT sinonasal and impairment subdomain scores significantly correlate with and are responsive to measures of CRS symptom severity (OSS), CRS‐specific QOL (SNOT‐22), and general QOL (EQ‐5D). The CRCT sinonasal subdomain is more reflective of sinonasal symptom burden and has an MCID for improvement/worsening of ≥ 3 points, while the impairment subdomain is more reflective of general QOL and has an MCID for improvement/worsening of ≥ 1 point. Conclusions: The CRCT sinonasal and impairment subdomain scores may serve as psychometrically validated outcome measures that provide additional insights into a patient's CRS disease state and overall CRS control in addition to the CRCT score. MCID values for the CRCT subdomain scores may serve as benchmarks for judging change in the subdomain scores. Level of Evidence: N/A
- Open Access
- 24 April 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (6) , 615-629
Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis
Background: Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS. Methods: Systematic literature search of PubMed, Embase, Scopus, and CINAHL databases for definitions of remission for chronic nonneoplastic diseases derived through consensus studies or society‐sponsored position papers. Remission definitions were extracted and common themes identified. Results: Thirty‐nine definitions of remission were identified, the majority (29/39) of which were for inflammatory diseases. Remission uniformly was a term describing a state of completely inactive or minimally active disease, often defined by criteria including patient‐reported outcomes, clinician‐reported outcomes, and results from physical examination or serological, histologic, imaging findings, or other disease‐specific testing. Definitions varied in specifying different categories/levels of remission. However, most definitions stipulated a specific purpose for remission as providing a unique positive prognostic benefit to patients, commonly as cessation of end‐organ damage/disease progression. Diseases that also utilized control as an outcome differentiated remission as a state of lesser disease activity. Conclusions: Commonalities from previously described remission definitions can be applied to define CRS remission as a state of minimal‐to‐no disease activity characterized by criteria reflecting the CRS disease process, the achievement of which would provide specific prognostic, future benefit to the patient. However, evidence is still lacking to support the utility or an exact definition of a remission construct for CRS.
- 24 April 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (6) , 615-629
Open AccessDisease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis
Background: Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS. Methods: Systematic literature search of PubMed, Embase, Scopus, and CINAHL databases for definitions of remission for chronic nonneoplastic diseases derived through consensus studies or society‐sponsored position papers. Remission definitions were extracted and common themes identified. Results: Thirty‐nine definitions of remission were identified, the majority (29/39) of which were for inflammatory diseases. Remission uniformly was a term describing a state of completely inactive or minimally active disease, often defined by criteria including patient‐reported outcomes, clinician‐reported outcomes, and results from physical examination or serological, histologic, imaging findings, or other disease‐specific testing. Definitions varied in specifying different categories/levels of remission. However, most definitions stipulated a specific purpose for remission as providing a unique positive prognostic benefit to patients, commonly as cessation of end‐organ damage/disease progression. Diseases that also utilized control as an outcome differentiated remission as a state of lesser disease activity. Conclusions: Commonalities from previously described remission definitions can be applied to define CRS remission as a state of minimal‐to‐no disease activity characterized by criteria reflecting the CRS disease process, the achievement of which would provide specific prognostic, future benefit to the patient. However, evidence is still lacking to support the utility or an exact definition of a remission construct for CRS.
- Open Access
- 15 April 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (7) , 1652-1660
Validation of Control Classifications Using the Chronic Rhinosinusitis Control Test as Comprehensive Reflections of Disease Burden
- 15 April 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (7) , 1652-1660
Open AccessValidation of Control Classifications Using the Chronic Rhinosinusitis Control Test as Comprehensive Reflections of Disease Burden
- 29 October 2025
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 46 (1) , 69-80
Diagnosis of Acute, Chronic (with and without Nasal Polyps), and Fungal Sinusitis
- 29 October 2025
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 46 (1) , 69-80
Diagnosis of Acute, Chronic (with and without Nasal Polyps), and Fungal Sinusitis
- Open Access
- 20 September 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (2) , 109-119
A cost utility analysis for the management of acute exacerbations of chronic rhinosinusitis
Background: The management of acute exacerbations of chronic rhinosinusitis (AECRS) is understudied and the most cost‐effective management of AECRS has not been previously investigated. The aim of this study is to determine the most cost‐effective strategy for the initial management of AECRS.Methods: The study design consisted of a decision‐tree economic model comparing three different initial strategies for managing a patient perceived AECRS: observation, upfront rescue medications, or clinic visit with diagnostic nasal endoscopy (DNE). The primary study outcome was the disease burden of a single AECRS, which was determined by the health utility value and the duration of symptoms. Strategies with an incremental cost‐effectiveness ratio < $50,000/quality‐adjusted life year (QALY) or equivalently < $137/quality‐adjusted life day (QALD) were considered cost‐effective.Results: Observation was the most cost‐effective strategy at a willingness to pay of $137 per QALD. One‐way sensitivity analysis demonstrated that observation was more effective than upfront rescue medications when the probability of bacterial infection as the cause of AECRS was <24.0%. Upfront rescue medications wer more cost effective than observation when the probability of bacterial infection exceeded 49.0%. Clinic visit with DNE was the most effective strategy to manage an AECRS, but it was not considered cost‐effective.Conclusion: Observation is the most cost‐effective strategy for the initial management of AECRS when there is a low likelihood of bacterial infection. When the probability of bacterial etiology of AECRS exceeds 49.0%, upfront rescue medications proved to be the most cost‐effective strategy.
- 20 September 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (2) , 109-119
Open AccessA cost utility analysis for the management of acute exacerbations of chronic rhinosinusitis
Background: The management of acute exacerbations of chronic rhinosinusitis (AECRS) is understudied and the most cost‐effective management of AECRS has not been previously investigated. The aim of this study is to determine the most cost‐effective strategy for the initial management of AECRS.Methods: The study design consisted of a decision‐tree economic model comparing three different initial strategies for managing a patient perceived AECRS: observation, upfront rescue medications, or clinic visit with diagnostic nasal endoscopy (DNE). The primary study outcome was the disease burden of a single AECRS, which was determined by the health utility value and the duration of symptoms. Strategies with an incremental cost‐effectiveness ratio < $50,000/quality‐adjusted life year (QALY) or equivalently < $137/quality‐adjusted life day (QALD) were considered cost‐effective.Results: Observation was the most cost‐effective strategy at a willingness to pay of $137 per QALD. One‐way sensitivity analysis demonstrated that observation was more effective than upfront rescue medications when the probability of bacterial infection as the cause of AECRS was <24.0%. Upfront rescue medications wer more cost effective than observation when the probability of bacterial infection exceeded 49.0%. Clinic visit with DNE was the most effective strategy to manage an AECRS, but it was not considered cost‐effective.Conclusion: Observation is the most cost‐effective strategy for the initial management of AECRS when there is a low likelihood of bacterial infection. When the probability of bacterial etiology of AECRS exceeds 49.0%, upfront rescue medications proved to be the most cost‐effective strategy.
- Open Access
- 14 September 2024
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 9 (5) , e70005
Patient perspectives on international multidisciplinary consensus criteria for chronic rhinosinusitis disease control
Objectives: Recently, a set of consensus criteria and near‐consensus criteria for the evaluation of chronic rhinosinusitis (CRS) disease control was identified by an international multidisciplinary panel of key stakeholders. The objective of this study is to evaluate patient perspectives on these disease control criteria.Methods: This is a qualitative phenomenological study using constant comparative methodology. Twenty‐one one‐on‐one interviews, ranging from 6 to 15 min and based on a standardized semi‐structured script, with CRS patients from diverse backgrounds were performed. The authors analyzed transcripts of the interviews to identify recurrent themes in patient responses. Conclusions were drawn based on these themes.Results: All participants agreed with the consensus criteria (overall symptom severity, nasal obstruction severity, patients' self‐assessed CRS control, and need for CRS‐related oral corticosteroids), and most participants agreed with near‐consensus criteria (nasal endoscopy, smell loss and nasal drainage severities, impairment of day‐to‐day activities, and overall quality of life) identified by the international multidisciplinary panel. Some patients disagreed with inclusion of smell loss due to common etiologies—such as post‐viral or iatrogenic causes—that would not necessarily be an indicator of active sinonasal inflammation. One theme that emerged was the need for a facial pain/pressure criterion to be added.Conclusions: CRS patients overwhelmingly affirmed recently described consensus and near‐consensus criteria for CRS disease control with the caveat that a question asking about facial pain/pressure should be included as well. Recently, identified consensus criteria for CRS disease control should be interpreted within the context of patient perspectives.
- 14 September 2024
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 9 (5) , e70005
Open AccessPatient perspectives on international multidisciplinary consensus criteria for chronic rhinosinusitis disease control
Objectives: Recently, a set of consensus criteria and near‐consensus criteria for the evaluation of chronic rhinosinusitis (CRS) disease control was identified by an international multidisciplinary panel of key stakeholders. The objective of this study is to evaluate patient perspectives on these disease control criteria.Methods: This is a qualitative phenomenological study using constant comparative methodology. Twenty‐one one‐on‐one interviews, ranging from 6 to 15 min and based on a standardized semi‐structured script, with CRS patients from diverse backgrounds were performed. The authors analyzed transcripts of the interviews to identify recurrent themes in patient responses. Conclusions were drawn based on these themes.Results: All participants agreed with the consensus criteria (overall symptom severity, nasal obstruction severity, patients' self‐assessed CRS control, and need for CRS‐related oral corticosteroids), and most participants agreed with near‐consensus criteria (nasal endoscopy, smell loss and nasal drainage severities, impairment of day‐to‐day activities, and overall quality of life) identified by the international multidisciplinary panel. Some patients disagreed with inclusion of smell loss due to common etiologies—such as post‐viral or iatrogenic causes—that would not necessarily be an indicator of active sinonasal inflammation. One theme that emerged was the need for a facial pain/pressure criterion to be added.Conclusions: CRS patients overwhelmingly affirmed recently described consensus and near‐consensus criteria for CRS disease control with the caveat that a question asking about facial pain/pressure should be included as well. Recently, identified consensus criteria for CRS disease control should be interpreted within the context of patient perspectives.
- Open Access
- 13 September 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (1) , 27-35
Patient‐reported disease control versus overall symptom severity as global metrics of chronic rhinosinusitis disease status
Background: Overall symptom severity (OSS) and patient‐reported chronic rhinosinusitis (CRS) control are global measures of CRS identified as consensus, essential criteria for CRS disease control assessment. We sought to determine the functional relationship between these two metrics.Methods: Using an international multicenter mixed‐methods design, 260 CRS patients were recruited. OSS score was measured using a visual analog scale. Patient‐reported CRS control was measured as “controlled,” “partly controlled,” and “uncontrolled.” Twelve participants underwent semi‐structured interviews to discuss OSS and patient‐reported CRS control.Results: The majority of interviewed participants felt OSS and patient‐reported CRS control measured different constructs—while OSS only measured symptoms, patient‐reported CRS control was more global, including not only symptom severity but also concepts such as medication usage, activity impairment, and exacerbations. Nevertheless, OSS score was strongly correlated with (ρ = 0.67, p < 0.001) and highly predictive of patient‐reported CRS control. OSS score of >4 (95% confidence interval [CI]: 1.8–4.2) had 74.7% sensitivity and 93.2% specificity in identifying patients reporting their CRS as not controlled. OSS score of >6.6 (95% CI: 4.1–7.1) had 77.0% sensitivity and 75.9% specificity in identifying patients reporting their CRS as uncontrolled. The 22‐item Sinonasal Outcome Test score was also predictive of patient‐reported CRS disease control but OSS was significantly more predictive.Conclusions: Patients conceptually view patient‐reported CRS control as a more global measure that subsumes OSS. Quantitatively, however, OSS is highly correlated with patient‐reported CRS control, possibly reflecting their redundancy. For ease of use, we recommend patient‐reported CRS control be reflected by OSS <4 for controlled, 4 ≤ OSS < 7 for partly controlled, and OSS ≥7 for uncontrolled CRS.
- 13 September 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (1) , 27-35
Open AccessPatient‐reported disease control versus overall symptom severity as global metrics of chronic rhinosinusitis disease status
Background: Overall symptom severity (OSS) and patient‐reported chronic rhinosinusitis (CRS) control are global measures of CRS identified as consensus, essential criteria for CRS disease control assessment. We sought to determine the functional relationship between these two metrics.Methods: Using an international multicenter mixed‐methods design, 260 CRS patients were recruited. OSS score was measured using a visual analog scale. Patient‐reported CRS control was measured as “controlled,” “partly controlled,” and “uncontrolled.” Twelve participants underwent semi‐structured interviews to discuss OSS and patient‐reported CRS control.Results: The majority of interviewed participants felt OSS and patient‐reported CRS control measured different constructs—while OSS only measured symptoms, patient‐reported CRS control was more global, including not only symptom severity but also concepts such as medication usage, activity impairment, and exacerbations. Nevertheless, OSS score was strongly correlated with (ρ = 0.67, p < 0.001) and highly predictive of patient‐reported CRS control. OSS score of >4 (95% confidence interval [CI]: 1.8–4.2) had 74.7% sensitivity and 93.2% specificity in identifying patients reporting their CRS as not controlled. OSS score of >6.6 (95% CI: 4.1–7.1) had 77.0% sensitivity and 75.9% specificity in identifying patients reporting their CRS as uncontrolled. The 22‐item Sinonasal Outcome Test score was also predictive of patient‐reported CRS disease control but OSS was significantly more predictive.Conclusions: Patients conceptually view patient‐reported CRS control as a more global measure that subsumes OSS. Quantitatively, however, OSS is highly correlated with patient‐reported CRS control, possibly reflecting their redundancy. For ease of use, we recommend patient‐reported CRS control be reflected by OSS <4 for controlled, 4 ≤ OSS < 7 for partly controlled, and OSS ≥7 for uncontrolled CRS.
- Open Access
- 7 November 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (5) , 2059-2069
Variability in Minimal Clinically Important Difference Calculation and Reporting in the Otolaryngology Literature
Objective: Best practices for calculation of the minimal clinically important difference (MCID) of outcome measures include the use of complementary methodologies (broadly classified as anchor‐based and distribution‐based) and reporting of the MCID's predictive ability. We sought to determine MCID calculation and reporting patterns within the otolaryngology literature.Methods: A systematic search strategy of Embase, PubMed, and Web of Science databases was developed and implemented to identify studies reporting the determination of an MCID for an outcome measure. Studies specifically within the otolaryngology literature (defined as journals classified as “otorhinolaryngology” in the Journal Citation Reports database) were included. All those journals were additionally searched for relevant articles.Results: There were 35 articles that met the inclusion criteria. Of these studies, 88.6% reported MCID of a patient‐reported outcome measure and the remainder were for objective outcome measurements. Anchor‐based methods were used by 82.9% of studies and distribution‐based methods were used by 68.6% of studies. Of all studies, 31.4% utilized anchor‐based methods alone, 17.1% utilized distribution‐based methods alone, and 51.4% used both methods. Only 25.7% of studies reported the sensitivity (median: 60.8%, range: 40.5%–86.7%) and specificity (median: 80.4%, range: 63.5%–88.0%) of the MCID to detect patients experiencing clinically important change.Conclusion: Deviation from best practices in MCID calculation and reporting exists within the otolaryngology literature, with almost half of all studies only using one method of MCID calculation and almost three‐quarters not reporting the predictive ability (sensitivity/specificity) of the calculated MCID. When predictive ability is reported, however, MCIDs appear to be more specific than sensitive.Level of Evidence: NA Laryngoscope, 134:2059–2069, 2024
- 7 November 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (5) , 2059-2069
Open AccessVariability in Minimal Clinically Important Difference Calculation and Reporting in the Otolaryngology Literature
Objective: Best practices for calculation of the minimal clinically important difference (MCID) of outcome measures include the use of complementary methodologies (broadly classified as anchor‐based and distribution‐based) and reporting of the MCID's predictive ability. We sought to determine MCID calculation and reporting patterns within the otolaryngology literature.Methods: A systematic search strategy of Embase, PubMed, and Web of Science databases was developed and implemented to identify studies reporting the determination of an MCID for an outcome measure. Studies specifically within the otolaryngology literature (defined as journals classified as “otorhinolaryngology” in the Journal Citation Reports database) were included. All those journals were additionally searched for relevant articles.Results: There were 35 articles that met the inclusion criteria. Of these studies, 88.6% reported MCID of a patient‐reported outcome measure and the remainder were for objective outcome measurements. Anchor‐based methods were used by 82.9% of studies and distribution‐based methods were used by 68.6% of studies. Of all studies, 31.4% utilized anchor‐based methods alone, 17.1% utilized distribution‐based methods alone, and 51.4% used both methods. Only 25.7% of studies reported the sensitivity (median: 60.8%, range: 40.5%–86.7%) and specificity (median: 80.4%, range: 63.5%–88.0%) of the MCID to detect patients experiencing clinically important change.Conclusion: Deviation from best practices in MCID calculation and reporting exists within the otolaryngology literature, with almost half of all studies only using one method of MCID calculation and almost three‐quarters not reporting the predictive ability (sensitivity/specificity) of the calculated MCID. When predictive ability is reported, however, MCIDs appear to be more specific than sensitive.Level of Evidence: NA Laryngoscope, 134:2059–2069, 2024